Advanced search
1 file | 253.05 KB

Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

Author
Organization
Abstract
Background: In a pilot study, the anti-tumour necrosis factor a monoclonal antibody, infliximab, induced a rapid and significant improvement in global, peripheral, and axial disease manifestations of patients with active spondyloarthropathy. Objective: To determine whether repeated infusions of infliximab would effectively and safely maintain the observed effect. Methods: Safety and efficacy of a maintenance regimen (5 mg/kg infliximab every 14 weeks) was evaluated using the measurements reported in the pilot study. Of the 21 patients, 19 completed the one year follow up for efficacy; two patients changed to another dosing regimen after week 12 owing to partial lack of efficacy. However, they are still being followed up for safety analysis. Results: After each re-treatment a sustained significant decrease of all disease manifestations was observed. Before re-treatment, symptoms recurred in 3/19 (16%) at week 20, in 13/19 (68%) at week 34 and in 15/19 (79%) at week 48. No withdrawals due to adverse events occurred. Twelve minor infectious episodes were observed. Twelve patients (57%) developed antinuclear antibodies; in four of them (19%) anti-dsDNA antibodies were detected. However, no lupus-like symptoms occurred. Conclusion: In this open study of infliximab in patients with active spondyloarthropathy, the significant improvement of all disease manifestations was maintained over a one year follow up period without major adverse events. Although recurrence of symptoms was noted in a rising number of patients before each re-treatment, no loss of efficacy was observed after re-treatment.
Keywords
SEVERE PSORIATIC-ARTHRITIS, NECROSIS-FACTOR-ALPHA, ANKYLOSING-SPONDYLITIS, RHEUMATOID-ARTHRITIS, CROHNS-DISEASE, FUNCTIONAL INDEX, DOUBLE-BLIND, PLACEBO, SULFASALAZINE, SPONDYLARTHROPATHY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 253.05 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Kruithof, Elli, Filip Van den Bosch, Dominique Baeten, A Herssens, Filip De Keyser, Herman Mielants, and Eric Veys. 2002. “Repeated Infusions of Infliximab, a Chimeric anti-TNFα Monoclonal Antibody, in Patients with Active Spondyloarthropathy: One Year Follow Up.” Annals of the Rheumatic Diseases 61 (3): 207–212.
APA
Kruithof, E., Van den Bosch, F., Baeten, D., Herssens, A., De Keyser, F., Mielants, H., & Veys, E. (2002). Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. ANNALS OF THE RHEUMATIC DISEASES, 61(3), 207–212.
Vancouver
1.
Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. ANNALS OF THE RHEUMATIC DISEASES. 2002;61(3):207–12.
MLA
Kruithof, Elli, Filip Van den Bosch, Dominique Baeten, et al. “Repeated Infusions of Infliximab, a Chimeric anti-TNFα Monoclonal Antibody, in Patients with Active Spondyloarthropathy: One Year Follow Up.” ANNALS OF THE RHEUMATIC DISEASES 61.3 (2002): 207–212. Print.
@article{164703,
  abstract     = {Background: In a pilot study, the anti-tumour necrosis factor a monoclonal antibody, infliximab, induced a rapid and significant improvement in global, peripheral, and axial disease manifestations of patients with active spondyloarthropathy. 
Objective: To determine whether repeated infusions of infliximab would effectively and safely maintain the observed effect. 
Methods: Safety and efficacy of a maintenance regimen (5 mg/kg infliximab every 14 weeks) was evaluated using the measurements reported in the pilot study. Of the 21 patients, 19 completed the one year follow up for efficacy; two patients changed to another dosing regimen after week 12 owing to partial lack of efficacy. However, they are still being followed up for safety analysis. 
Results: After each re-treatment a sustained significant decrease of all disease manifestations was observed. Before re-treatment, symptoms recurred in 3/19 (16%) at week 20, in 13/19 (68%) at week 34 and in 15/19 (79%) at week 48. No withdrawals due to adverse events occurred. Twelve minor infectious episodes were observed. Twelve patients (57%) developed antinuclear antibodies; in four of them (19%) anti-dsDNA antibodies were detected. However, no lupus-like symptoms occurred. 
Conclusion: In this open study of infliximab in patients with active spondyloarthropathy, the significant improvement of all disease manifestations was maintained over a one year follow up period without major adverse events. Although recurrence of symptoms was noted in a rising number of patients before each re-treatment, no loss of efficacy was observed after re-treatment.},
  author       = {Kruithof, Elli and Van den Bosch, Filip and Baeten, Dominique and Herssens, A and De Keyser, Filip and Mielants, Herman and Veys, Eric},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keywords     = {SEVERE PSORIATIC-ARTHRITIS,NECROSIS-FACTOR-ALPHA,ANKYLOSING-SPONDYLITIS,RHEUMATOID-ARTHRITIS,CROHNS-DISEASE,FUNCTIONAL INDEX,DOUBLE-BLIND,PLACEBO,SULFASALAZINE,SPONDYLARTHROPATHY},
  language     = {eng},
  number       = {3},
  pages        = {207--212},
  title        = {Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up},
  url          = {http://dx.doi.org/10.1136/ard.61.3.207},
  volume       = {61},
  year         = {2002},
}

Altmetric
View in Altmetric
Web of Science
Times cited: